Precigen (PGEN) to Release Earnings on Wednesday

Precigen (NASDAQ:PGEN) is expected to be posting its Q4 2025 results after the market closes on Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $8.2860 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:30 PM ET.

Precigen Stock Performance

PGEN stock opened at $3.28 on Monday. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.04 and a quick ratio of 3.95. Precigen has a 1 year low of $1.11 and a 1 year high of $5.47. The company has a market cap of $1.16 billion, a P/E ratio of -2.36 and a beta of 1.10. The stock’s fifty day moving average price is $4.17 and its 200-day moving average price is $4.00.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Thursday, January 22nd. Zacks Research upgraded Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.50.

Institutional Investors Weigh In On Precigen

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd bought a new position in Precigen in the 3rd quarter worth $39,000. Russell Investments Group Ltd. purchased a new stake in Precigen in the third quarter worth about $41,000. Mason Investment Advisory Services Inc. purchased a new stake in Precigen in the fourth quarter worth about $42,000. Abel Hall LLC bought a new position in shares of Precigen in the fourth quarter worth about $44,000. Finally, NewEdge Advisors LLC bought a new position in shares of Precigen in the fourth quarter worth about $45,000. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.